Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses

Vaccine

Volumn 29, Issue 22, 2011, Pages 3842-3849

  Rumke H C ^a   Loch, H P ^b   Hoppenbrouwers, K ^c   Vandermeulen, C ^c   Malfroot, A ^d   Helm, K ^e   Douha, M ^f   Willems, P ^f  

^a University Vaccine Center Rotterdam Nijmegen   (Netherlands)

^b Medical Practice Wolfenbüttel   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e Pediatric Office   (Germany)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Dose interval; Immunogenicity; Measles mumps rubella varicella vaccine; Safety

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG; CHICKENPOX VACCINE; MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE;

BLOOD SAMPLING; CHICKENPOX; COMPARATIVE STUDY; DRUG DOSE REGIMEN; FEVER; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEASLES; MENINGISM; MUMPS; PAROTITIS; PRIORITY JOURNAL; RASH; REVIEW; RUBELLA; SALIVARY GLAND DISEASE; VACCINATION; VIRUS STRAIN; AGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; IMMUNOLOGY; INFANT; MALE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; CHICKENPOX VACCINE; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 80051717455     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.067     Document Type: Review

References (36)

1. World Health Organization. Measles vaccines. Wkly Epidemiol Rec 2004;79:130-42.
2. Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P. The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ 2004;5(1):46-53.
3. Bonhoeffer J, Baer G, Muehleisen B, Aebi C, Nadal D, Schaad U, et al. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr 2005;164(6):366-70.
4. Ramet J. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella. Int J Infect Dis 2007;11(Suppl. 2):S49-55.
5. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000;182(2):383-90.
6. Centers for Disease Control and Prevention. In: AtkinsonW, Hamborsky J, McIntyre L, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 10th edn. Washington, DC: Public Health Foundation; 2007.
7. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2007;82:51-60.
8. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 2008;27(8):724-30.
9. Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002;21(3-4):281-9.
10. Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006;25(1):12-8.
11. Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007;35(5):326-33.
12. Shinefield H, Black S, Digilio L. Evaluation of a Quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Peadiatr Infect Dis J 2005;24:665-9.
13. Marcy SM. Pediatric combination vaccines: their impact on patients, providers, managed care organizations, and manufacturers. Am J Manage Care 2003;9:314-20.
14. Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine 2007;25(42):7307-12.
15. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 2007;26(2):153-8.
16. Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J 2007;26(7):632-8.
17. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40.
18. Rentier B, Gershon AA. and the members of EuroVar the European Working Group on Varicella (EuroVar). A consensus paper: varicella vaccination of healthy children-a challenge for Europe. Pediatr Infect Dis J 2004;23(5):379-89.
19. World Health Organization. Wkly Epidemiol Rec 2004;79(14):129-44.
20. Robert Koch Institute. Bekämpfung der Mäsern und konnatalen Röteln: WHOStrategie in der Europäischen Region und aktueller Stand in Deutchland. Epidemiol Bull 2004;10:79-83.
21. Centers for Disease Control. Simultaneous administration of varicella vaccine and other recommended childhood vaccine. MMWR Morb Mortal Wkly Rep 2001;50(47):1058-61.
22. Centers for Disease Control. Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization. MMWR Recomm Rep 1994;43(RR-1):23.
23. Landry ML, Cohen SD, Mayo DR, Fong CK, Andiman WA. Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus. J Clin Microbiol 1987;25(5):832-5.
24. Martins TB, Jaskowski TD, Schroder C, Streeter B, Hill HR. Comparison of three commercially available assays for detection of varicella-zoster virus antibody. Clin Diagn Lab Immunol 1994;1(2):186-8.
25. Clopper, Pearson. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika 1934;26:404-13.
26. Brunell PA, Brickman A, Steinberg S. Evaluation of a live attenuated mumps vaccine (Jeryl Lynn). With observations on the optimal time for testing serologic response. Am J Dis Child 1969;118(3):435-40.
27. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004;190(477):83.
28. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. NEJM 2002;347(24):1909-15.
29. Gershon AA. Varicella vaccine-are two doses better than one? (Editorials). NEJM 2002;347(24):1962-3.
30. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008;8(12):796-803.
31. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008;47(11):1458-67.
32. Vandermeulen C, Roelants M, Vermoere M, Rosseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004;22:2713-6.
33. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year followup. J Infect Dis 2008;197:950-6.
34. Zepp F, Behre U, Kindler K, Laakmann KH, Pankow-Culot H, Mannhardt-Laakmann W, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007;166(8): 857-64.
35. Knuf M, Faber J, Barth I, Habermehl P. A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc) 2008;44(4): 279-92.
36. Jacobsen SJ, Ackerson BK, Sy LS, Tran TL, Jones TL, Yao JF, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a management care setting. Vaccine 2009;27:4656-61.